Allogeneic Peptide-Major Histocompatibility Complex (allo-pMHC)

The allogeneic peptide-major histocompatibility complex (allo-pMHC) is the fundamental molecular target recognized by donor T cells during the development of Graft-versus-Host Disease (GvHD) and the Graft-versus-Leukemia (GvL) effect. These complexes consist of recipient-derived polymorphic peptides, such as minor histocompatibility antigens (MiHAs) or mismatched human leukocyte antigens (HLA), presented on the cell surface by MHC molecules. When these antigens are shared—meaning they are expressed on both recipient hematopoietic cells and non-hematopoietic tissues—they trigger an alloreactive T-cell response that leads to systemic tissue damage. This recognition is the primary driver of acute and chronic GvHD, which affects organs like the skin, liver, and gastrointestinal tract. Conversely, antigens restricted to the hematopoietic system are ideal targets for promoting GvL without inducing GvHD. Therapeutic intervention typically involves the use of immunosuppressive drugs like calcineurin inhibitors or costimulation blockers to prevent T-cell recognition and activation. For example, abatacept blocks the costimulatory signals required for T cells to respond to these complexes. Other drugs like ruxolitinib inhibit the downstream signaling pathways activated upon TCR-MHC interaction. Monitoring these interactions through HLA typing and MiHA genotyping is critical for donor selection and predicting transplant outcomes.

Other names

Minor Histocompatibility Antigen-MHC complexAlloantigen-MHC complexRecipient hematopoietic and non-hematopoietic normal cells presenting shared allogeneic peptide–MHC complexesMiHA-HLA complexBroadly expressed minor histocompatibility antigen

Immunosuppressive and immunomodulatory drugs act by blocking the costimulatory signals, signaling pathways, or effector functions of T cells that recognize these allogeneic complexes, thereby preventing or treating Graft-versus-Host Disease.